Sino Biopharmaceutical (SBMFF) Stock Statistics & Valuation Metrics

Sino Biopharmaceutical has a market cap or net worth of $8.19B. The enterprise value is $55.37B.

Sino Biopharmaceutical has 18.77B shares outstanding. The number of shares has decreased by -2.65% in one year.

Sino Biopharmaceutical’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 9.45%.

The current PE Ratio of Sino Biopharmaceutical is 30.45. Sino Biopharmaceutical’s PEG ratio is -0.43.

In the last 12 months, Sino Biopharmaceutical had revenue of $15.87B and earned $3.02B in profits. Earnings per share was $0.06.

In the last 12 months, operating cash flow was $3.08B and capital expenditures -$407.50M, giving a free cash flow of $2.67B billion.

Sino Biopharmaceutical pays an annual dividend of <$0.01, resulting in a dividend yield of 1.69%

Sino Biopharmaceutical upcoming earnings date is Aug 28, 2025, TBA.

Sino Biopharmaceutical as a current ratio of 1.05, with Debt / Equity ratio of 0.41

In the past 12 months, Sino Biopharmaceutical has paid $614.09M in taxes.

Sino Biopharmaceutical EV to EBITDA ratio is 10.62, with an EV/FCF ratio of 17.00.

Sino Biopharmaceutical has $13.18B in cash and marketable securities with $9.68B in debt, giving a net cash position of -$3.50B billion.

Gross margin is 80.95%, with operating margin of 22.08%, and net profit margin of 8.90%.

The average price target for Sino Biopharmaceutical is $0.57, which is 11.43% higher than the current price. The consensus rating is Moderate Buy